A retrospective, new-user comparative cohort study revealed that angiotensin receptor blockers (ARBs) do not differ statistically significantly in effectiveness at the class level compared with ACE (angiotensin-converting enzyme) inhibitors as first-line treatment for high blood pressure but present a better safety profile. The study included all patients with high blood pressure initiating monotherapy with an ACE inhibitor (n=2 297 881) or ARB (n=673 938) between 1996 and 2018 across 8 databases from the United States, Germany, and South Korea. There was no statistically significant difference in the primary outcomes of acute myocardial infarction (hazard ratio [HR], 1.11 for ACE versus ARB), heart failure (HR, 1.03), stroke (HR, 1.07), or composite cardiovascular events (HR, 1.06). Across secondary and safety outcomes, patients on ARBs had significantly lower risk of angioedema, cough, pancreatitis, and GI bleeding. The findings support preferentially prescribing ARBs over ACE inhibitors when initiating treatment although both classes are guideline-recommended first-line treatments for high blood pressure. Source: https://www.ahajournals.org/
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2…
A new study investigating the link between cerebral microbleeds (CMBs) and dementia has found that…
A comprehensive prospective study tracking over 159,000 adults for up to three decades has provided…
A comprehensive new Cochrane review of 22 studies involving nearly 2,000 participants over six months…
A large-scale study involving 103,649 UK Biobank participants has revealed that adhering to healthy dietary…
To address uncertainties in statin safety profiles, which are often based on observational data susceptible…
This website uses cookies.